コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 s an excellent inhibitory specificity toward tissue kallikrein.
2 nhibitor (serpin) that specifically inhibits tissue kallikrein.
3 2 cleft generated by Tyr(99) and Trp(219) of tissue kallikrein.
4 s at P3 display better binding activity with tissue kallikrein.
5 e the inhibitory activity of a serpin toward tissue kallikrein.
6 Asp(98J) and hydrogen bond with Gln(174) of tissue kallikrein.
7 say between serum KBP and (125)I-labeled rat tissue kallikrein.
8 was determined by its complex formation with tissue kallikrein.
9 o, independent of regulating the activity of tissue kallikrein.
10 peptidase 7 (KLK7) is a member of the human tissue kallikreins.
13 chronic administration of recombinant human tissue kallikrein-1 protein (DM199) to non-obese diabeti
14 eveloped and tested DM199, recombinant human tissue kallikrein-1 protein (rhKLK-1), as a potential no
15 about the role of kallikreins, in particular tissue kallikrein-1, in type 1 diabetes mellitus (T1D).
16 esponses is well documented, but the role of tissue kallikrein-1, the protease that generates bradyki
17 allergic sheep was associated with increased tissue kallikrein activity (TK) and decreased alpha-1-pr
18 ontained immunoreactive BK and BK precursor, tissue kallikrein activity, and bradykinin-destroying en
21 eparin-suppressed inhibitory activity toward tissue kallikrein and exhibited an inhibitory activity 2
22 onents, kallikrein-binding protein, binds to tissue kallikrein and inhibits its activity in vitro.
24 milar in sequence to neuropsin, trypsin, and tissue kallikrein and is predicted to have trypsin-like
25 the effect of porcine and human recombinant tissue kallikrein and plasma kallikrein on [Ca(2+)](i) m
26 ), (2) BAL levels of the inflammatory marker tissue kallikrein, and (3) numbers of inflammatory cells
27 nhibitory activities of these mutants toward tissue kallikrein are in the order of P2 Phe (wild type)
30 accelerate the association of a serpin with tissue kallikrein by acting as a secondary binding site.
32 ermining inhibitory specificity toward human tissue kallikrein by site-directed mutagenesis and molec
34 specific serine protease and a member of the tissue kallikrein family, is a zymogen composed of 228 a
36 nthetic peptide-based inhibitor specific for tissue kallikrein (FE999024) was used in our studies to
37 (KLK)4 is a recently described member of the tissue kallikrein gene family that is specifically expre
43 hibitory activities of the P1 mutants toward tissue kallikrein in the order of P1 Arg > P1 Phe > P1 L
45 kallistatin bound to the reactive crevice of tissue kallikrein indicated that the P2 residue required
46 ix and C2 sheet of kallistatin is crucial in tissue kallikrein inhibition, and this functional loop c
49 ypsin, a non-heparin-binding serpin and slow tissue kallikrein inhibitor as a scaffold to engineer ka
52 to milk, BK, together with its precursor and tissue kallikrein, is continuously released into the vas
53 inhibited human plasmin (Ki = 0.1 nM), human tissue kallikrein (Ki = 0.1 nM), human plasma kallikrein
56 +/- 59 pg BK equivalents ml(-1) and that of tissue kallikrein, measured as cleavage of D-Val.Leu.Arg
57 f the kallikrein-kinin system are plasma and tissue kallikreins, proteases that cleave high molecular
60 Phe displays a better selectivity for human tissue kallikrein than P1 Arg, since P1 Arg also inhibit
61 ing specific protease inhibitors showed that tissue kallikrein (TK) processed pro-EGF in response to
62 (HA), in vitro, binds and inactivates airway tissue kallikrein (TK), the enzyme responsible for kinin
63 eptidase M); however, receptor activation by tissue kallikrein, trypsin, or cathepsin G was not affec
64 atin, the binding activity of K187A/K188A to tissue kallikrein was blocked by heparin, whereas K307A/